Therapure Biopharma Inc. Delays Initial Public Offering

Therapure Biopharma Inc. has postponed its proposed initial public offering due to current conditions in capital markets.
According to the company’s press release:

While the business is performing above expectations and investor feedback about the quality of management and the company was very positive, the company makes this decision in light of the current market environment, in which no IPOs were concluded in the U.S. or Canada in January.

Steve Ottaway, Managing Director of Investment Banking at GMP Securities L.P.:

We believe that Therapure is the type of company Canadian public investors would want to add to their portfolios, and we will continue to work with Catalyst and Therapure’s management to evaluate capital market conditions.

Click here to view the full press release.